Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 plus sunitinib in metastatic renal cell carcinoma
2008-006210-14Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2009
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trebananib and sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Amgen. Primary endpoint: Safety and tolerability. Started Mar 2009; status: completed.
02
Drugs
trebananibsunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-006210-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006210-14.